Key Points
- Director Joseph Wender sold 28,000 shares on December 1 at an average price of $80.82 for a total of $2,262,960, cutting his position by 43.73% to 36,035 shares; the transaction was disclosed in an SEC filing.
- Company performance and analyst view: Ionis has a $13.26B market cap and a 52‑week range of $23.95–$83.09, reported Q3 revenue of $156.72M with EPS of -$0.80 (beating estimates), and holds a consensus "Moderate Buy" rating with a $84.15 price target.
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report) Director Joseph Wender sold 28,000 shares of the firm's stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $80.82, for a total value of $2,262,960.00. Following the transaction, the director owned 36,035 shares of the company's stock, valued at $2,912,348.70. This trade represents a 43.73% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Ionis Pharmaceuticals Stock Performance
Ionis Pharmaceuticals stock opened at $81.84 on Thursday. The firm has a market capitalization of $13.26 billion, a P/E ratio of -48.43 and a beta of 0.30. The stock has a fifty day moving average price of $72.86 and a two-hundred day moving average price of $53.89. Ionis Pharmaceuticals, Inc. has a 52-week low of $23.95 and a 52-week high of $83.09. The company has a debt-to-equity ratio of 0.96, a current ratio of 2.79 and a quick ratio of 2.78.
Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) last announced its earnings results on Wednesday, October 29th. The company reported ($0.80) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.15) by $0.35. Ionis Pharmaceuticals had a negative net margin of 26.45% and a negative return on equity of 44.26%. The business had revenue of $156.72 million during the quarter, compared to analysts' expectations of $131.75 million. During the same quarter last year, the company posted ($0.95) EPS. The firm's revenue for the quarter was up 17.2% on a year-over-year basis. As a group, analysts anticipate that Ionis Pharmaceuticals, Inc. will post -3.5 EPS for the current fiscal year.
Analyst Ratings Changes
A number of research analysts recently issued reports on IONS shares. Guggenheim lifted their price target on Ionis Pharmaceuticals from $90.00 to $92.00 and gave the company a "buy" rating in a report on Tuesday, September 23rd. Wells Fargo & Company lifted their price objective on Ionis Pharmaceuticals from $77.00 to $82.00 and gave the company an "overweight" rating in a report on Friday, August 22nd. Stifel Nicolaus raised their price target on shares of Ionis Pharmaceuticals from $43.00 to $67.00 and gave the stock a "hold" rating in a research note on Monday, October 6th. Bank of America raised their target price on shares of Ionis Pharmaceuticals from $81.00 to $83.00 and gave the company a "buy" rating in a research note on Tuesday, September 23rd. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Ionis Pharmaceuticals in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, Ionis Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus price target of $84.15.
Read Our Latest Report on IONS
Institutional Trading of Ionis Pharmaceuticals
Several large investors have recently made changes to their positions in IONS. Golden State Wealth Management LLC boosted its stake in Ionis Pharmaceuticals by 198.4% in the third quarter. Golden State Wealth Management LLC now owns 376 shares of the company's stock valued at $25,000 after buying an additional 250 shares in the last quarter. Steigerwald Gordon & Koch Inc. bought a new position in shares of Ionis Pharmaceuticals in the third quarter worth about $25,000. Mather Group LLC. acquired a new stake in shares of Ionis Pharmaceuticals in the 3rd quarter valued at approximately $27,000. Quarry LP bought a new stake in shares of Ionis Pharmaceuticals during the 3rd quarter valued at approximately $38,000. Finally, Johnson Financial Group Inc. bought a new stake in shares of Ionis Pharmaceuticals during the 3rd quarter valued at approximately $44,000. Institutional investors and hedge funds own 93.86% of the company's stock.
Ionis Pharmaceuticals Company Profile
(
Get Free Report)
Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
